Year: 2021
Type: review
Abstract: This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors' own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.
Institutions: University of Alabama at Birmingham, University of Louisville, University of Minnesota, Cedars-Sinai Medical Center, Cedars-Sinai Smidt Heart Institute, Inserm, Université Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center, Universitätsmedizin Göttingen, German Centre for Cardiovascular Research, University of Wisconsin–Madison, Stanford Cardiovascular Institute, Stanford University, Duke University, Duke Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,600
Awards: Endogenous and exogenous mechanisms that promote myocardial remuscularization in post infarction LV remodeling, Integrated Cellular and Tissue Engineering for Ischemic Heart Disease, Deciphering the Neonatal Cardiac Regenerative Potential and Regulators in Large Animals, Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytes, Induction of Cardiomyocyte Proliferation via Transient Expression of Cell Cycle Factors as a Promising Therapy for Heart Failure
OpenAlex ID: W3212725035